# Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.

> **NCT02070211** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Bambino Gesù Hospital and Research Institute** · enrollment: 80 (estimated)

## Conditions studied

- 22q11 Deletion Syndrome

## Interventions

- **DIETARY_SUPPLEMENT:** omega-3 PUFAs
- **OTHER:** Standard care
- **DIETARY_SUPPLEMENT:** placebo

## Key facts

- **NCT ID:** NCT02070211
- **Lead sponsor:** Bambino Gesù Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2014-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070211, "Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02070211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*